EBAMed raises EUR 14.35 million in series A funding for non-invasive ventricular tachycardia treatment

EBAMed Secures EUR 14.35 Million in Series A Funding to Advance Non-Invasive Treatment for Ventricular Tachycardia

EBAMed, a Geneva-based company specializing in the development of novel image guidance systems for ventricular arrhythmias, announced raising of 14.35 M € in series A funding to accelerate the development of an innovative device to advance cardiac radiation ablation therapy. The financing round was led by Panakès Partners, a venture capital firm with headquarters in Milan, together with the EIC Fund, Swiss EFI Lake Geneva Ventures, LIFTT Venture Capital Italia, and OCCIDENT. The round was also supported by existing investors, including Mayo Clinic.

The funding will be used to develop further their innovative CardioKit system, aimed at advancing the non-invasive treatment of ventricular tachycardia through Proton Therapy. The funding round was led by Panakès Partners and supported by prominent investors, including Mayo Clinic, to propel the development and potential impact of this groundbreaking medical technology.

The fund will be used to bring EBAMed’s CardioKit system - a device that automatically adjusts cardiac radiation ablation systems for cardiac motion and increases external beam delivery precision – up to the completion of its First Human trials.

The development of a radiation therapy approach, combined with unique motion monitoring and gating solution, will fill an important need for alternatives to either drug therapy or catheter-based ablation and for reduced radiation of healthy myocardium.

“It is our mission to optimize radiotherapy for Cardiac Indications. With recent exciting developments towards compensation for cardiorespiratory movements, we believe our technology has the potential to revolutionize the treatment of cardiac arrhythmias. The new funding will help us bring our groundbreaking technology to patients in need and become a key component in the future non-invasive ablation treatment pathway for life-threatening arrhythmias,” said Marina Izzo, CEO of EBAMed.

Published on : 10th July, 2023